HELLP Syndrome Clinical Trial
Official title:
General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome
Verified date | April 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anesthesia for caesarian section in patients with HELLP syndrome is a challenge. Measures should be taken during caesarian delivery to guard against the maternal and fetal complications associated with HELLP syndrome.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 1, 2018 |
Est. primary completion date | December 1, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: Patients with class (II) (12) HELLP syndrome scheduled for elective caesarian section: Diagnosis of HELLP syndrome was based on the clinical diagnosis of preeclampsia and the following laboratory abnormalities (13): 1. Hemolysis: characteristic peripheral blood smear, serum lactic dehydrogenase (LDH) = 600 U/ l, total bilirubin = 1.2 mg /dl, decreased hemoglobin and hematocrit. 2. Elevated liver enzymes, defined as aspartate aminotransferase (AST). = 70 U/ l, alanin aminotransferase (ALT) = 50 U/ l and lactate dehydrogenase (LDH) = 600 U/ l. 3. Low platelet count: class 2 HELLP having a platelet nadir between > 50000 and 100000 mm-3. Exclusion Criteria: 1. Emergency cases 2. Placenta praevia 3. Cardiovascular or cerebrovascular disease. 4. Morbid obesity with a BMI =40 5. Gestational age <36 or >41 weeks 6. Platelet counts less than 50000 mm-3; class 1 HELLP and class 3 HELLP having platelet count more than 100 000 mm-3 |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut university hospital, Faculty of medicine | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of perioperative mortality in both groups. | Maternal | up to one week postoperative | |
Secondary | occurence bradycardia | heart rate less than 50 beat/min | up to 24 hours postoperative | |
Secondary | occurrence of tachycardia | heart rate more than 120 beats/min | up to 24 hours postoperative | |
Secondary | occurrence of hypotension | mean arterial blood pressure < 40% of the baseline | up to 24 hours postoperative | |
Secondary | occurrence of hypertension | mean arterial blood pressure > 40% of the baseline | up to 24 hours postoperative | |
Secondary | incidence of cerebral hemorrhage | detected by CT in patients with neurological deficits | up to one week postoperative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Terminated |
NCT04725812 -
Complement Regulation to Undo Systemic Harm in Preeclampsia
|
Phase 2 | |
Recruiting |
NCT02020174 -
The Preeclampsia Registry
|
||
Recruiting |
NCT06377878 -
The Preeclampsia Registry
|
||
Recruiting |
NCT02920593 -
A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy
|
Phase 4 | |
Recruiting |
NCT01138839 -
Dexamethasone Efficacy in HELLP I Syndrome
|
Phase 3 | |
Recruiting |
NCT05500989 -
PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
|
||
Completed |
NCT04216706 -
Early Vascular Adjustments to Prevent Preeclampsia
|
||
Recruiting |
NCT03834285 -
Liver Disease in Pregnancy
|
||
Completed |
NCT00000534 -
Calcium for Pre-Eclampsia Prevention (CPEP)
|
Phase 3 | |
Recruiting |
NCT02807324 -
Women Specific Cardiac Recovery After Preeclampsia
|
||
Completed |
NCT01736826 -
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
|
||
Terminated |
NCT00711841 -
Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome
|
Phase 4 | |
Completed |
NCT00097110 -
RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil
|
Phase 3 | |
Completed |
NCT03715647 -
Correlation of Survival in Puerperae by Electrical Impedance Tomography
|
||
Completed |
NCT03455387 -
Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.
|
||
Completed |
NCT03246542 -
Promising Bimarker Prediction of Outcome of HELLP Syndrome.
|
N/A | |
Completed |
NCT03232359 -
Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome
|
N/A |